Rehan Khan Explores Clopidogrel
Rehan Khan, Hospital Pharmacist and Manager Auctus Hospital, shared on LinkedIn:
”Day 2/365 – Medicine of the Day: CLOPIDOGREL
One-Sentence Definition
Clopidogrel is an antiplatelet drug used to prevent blood clot formation in patients with cardiovascular and cerebrovascular diseases.
Pharmacological Overview
Drug class: Antiplatelet agent (P2Y₁₂ receptor inhibitor)
Drug type: Prodrug
Primary role: Prevention of arterial thrombosis
Therapeutic Uses
- Acute Coronary Syndrome (ACS)
- Post–myocardial infarction (MI)
- Stroke and TIA prevention
- After coronary stent placement
- Alternative in aspirin intolerance
Mechanism of Action (MOA)
- Inhibits ADP (P2Y₁₂) receptors on platelets
- Prevents activation of GPIIb/IIIa complex
- Lowers Platelet aggregation
- Effect lasts for platelet lifespan (7–10 days)
Common Dose
- Maintenance dose: 75 mg once daily
- Loading dose (ACS/PCI): 300–600 mg stat
Key Adverse Effects
Bleeding (most common)
Gastrointestinal upset
Rare: Thrombotic thrombocytopenic purpura (TTP)
Clinical Pearl
Clopidogrel is a prodrug—its efficacy depends on liver enzyme activation (CYP2C19).
HISTORY OF CLOPIDOGREL
1980s: Development of thienopyridine antiplatelets
1997: Clopidogrel approved for clinical use
CAPRIE trial: Showed superiority over aspirin in reducing ischemic events
Modern era: Backbone of dual antiplatelet therapy (DAPT) with aspirin
Why Clopidogrel Matters
- Essential in cardiology and interventional practice
- Life-saving in stent patients
- WHO essential cardiovascular medicine
Widely used globally in ACS protocols”
Stay updated with Hemostasis Today.
-
Aug 21, 2026, 21:58Toby Richards: WEHI Trial Solidifies IV Iron as Third-Trimester Standard
-
Aug 21, 2026, 21:51Mehak Trehan: From Reading the Chapter to Writing One
-
Aug 21, 2026, 21:38Ann Reilly: Navigating Postoperative vs. Acute Blood Loss Anemia – A CDI Case Study
-
Aug 21, 2026, 21:29Merlin Crossley: Atomic Precision in Sickle Cell Care – Structural Targeting for Fetal Globin Reactivation
-
Aug 21, 2026, 19:09Aphisit Thongthaisin: Admitted to Sorbonne University’s T2H University Diploma for 2026/2027
-
Aug 21, 2026, 19:07José Luis Ferreiro Gutiérrez: Proud to Be Elected Chairperson-Elect of the ESC Working Group on Thrombosis
-
Aug 21, 2026, 19:00Manuel Monreal: New RIETE Registry Data on VTE Recurrence and Bleeding During Anticoagulation
-
Aug 21, 2026, 18:39Ronak H. Mistry: Updated ASH ITP Guidelines Bring New Guidance for Managing ITP
-
Aug 21, 2026, 18:22Ahmed Bennis: NOAC Use Is Associated With Slower Cognitive Decline in AF and Alzheimer’s Disease